Important progress made in the screening of anti-2019 coronavirus drugs in Wuhan virus

According to the website of the Wuhan Virus Institute of the Chinese Academy of Sciences, February 4, the Wuhan Virus Research Institute of the Chinese Academy of Sciences /Biosecurity Research Center and the National Research Center for Emergency Prevention and Control drug engineering and technology of the Military Academy of Sciences conducted a joint study to make important progress in curbing the screening of the 2019 new coronavirus (2019-nCoV) drug.

The results of the study were “Remdesivir and chloroquine annol inhibit the recent emergly ed novel coronavirus (2019-nCoV) in vitro” (Reedsiwe and Chlorpyrifos phosphate effectively inhibits new coronaviruses (2019-nCoV) in vitro) in the title published in Cell Research, an internationally renowned academic journal of China’s independent intellectual property rights.

The study showed that on Vero E6 cells, Reedsivir (GS-5734) had an effective concentration of EC50-0.77 uM (micromole per liter) for half of the 2019-nCoV, with a choice of exponential SI greater than 129 The EC50 s 1.13 uM of chloroquine phosphate (Chloroquine) and sI greater than 88 indicate that the two drugs can effectively inhibit the infection of 2019-nCoV at the cellular level, and their effect on human body has yet to be clinically verified.

Important progress made in the screening of anti-2019 coronavirus drugs in Wuhan virus

In vitro antiviral activity test of the drug against the new coronavirus (2019-nCoV)

Remdesivir (GS-5734) is a nucleoside analogue and is currently being clinically studied in phaseII and PHASE III for the treatment of Ebola haemorrhagic fever in the Democratic Republic of the Congo. Chloroquine phosphate (chloroquine) has been used to treat malaria since the 1940s and later to treat rheumatoid arthritis. The preliminary results of the two drugs’ effective suppression of the 2019 new coronavirus infection at the cellular level have previously been reported to the relevant national and provincial authorities in various forms. In order to serve the epidemic prevention and control, the two partners jointstatement: In the above-mentioned anti-2019 new coronavirus effect of drugs, we have been listed in The domestic and can fully realize the independent supply of the drug chloroquine phosphate, do not apply for relevant patents, in order to encourage relevant enterprises to participate in the outbreak prevention and control enthusiasm; And the drug ridsewewe, which has intellectual property barriers, in accordance with international practice and from the point of view of protecting national interests, filed a Patent for Chinese Inventions (the use of a new type of coronavirus in 2019) on January 21st, and will enter major countries around the world through the PCT (Patent Cooperation Agreement). If foreign related enterprises intend to contribute to the prevention and control of China’s epidemic, we agree that in the case of national needs, do not require the implementation of the patent claims rights, hope to work together with foreign pharmaceutical companies for the outbreak prevention and control efforts.

Wang Manli Researcher of Wuhan Virus Institute, Cao Ruiyuan Associate Researcher of the National Center for Emergency Prevention and Control drug Engineering and Technology Research Center of the Military Medical Research Institute, Zhang Leixuan Associate Researcher of Wuhan Virus Institute, And Yang Xingxuan Associate Researcher as the first author of the paper, Researcher Xiao Weifu of Wuhan Virus Institute, Zhong Wu, a researcher at the National Center for Emergency Prevention and Control drug engineering and technology at the Military Medical Research Institute, and Hu Zhihong, a researcher at Wuhan Virus Institute, are co-authors, and Liu Jia, Xu Mingyue and Shi Zhengli are co-authors. Also participating in the research of the project are Wang Xi, Wu Wei, Shang Weixuan, Zhang Huanyu, Li Yufeng, Hu Hengrui, Jiang Xiaming, Sun Yuan and so on. The work has been strongly supported by the National Virus Resource Bank and Wuhan National Biosecurity Laboratory, as well as the National Science and Technology Special Project (2018ZX09711003), The National Natural Science Foundation Innovation Group Project (31621061) and Hubei Province 2019 New Pneumonia Emergency Science and Technology Research Project.

Related links https://www.nature.com/articles/s41422-020-0282-0